drugset / Trial / NCT04611256
Mesenchymal Stem Cells in Patients Diagnosed With COVID-19
Phase 1
Unknown
20 enrolled
Hospital Reg. Lic. Adolfo Lopez Mateos
Instituto de Terapia Celular: ITC · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The propose of this study is implement adjuvant therapy with adipose tissue derived-mesenchymal stem cells (MSCs) for critical COVID-19 patients admitted to the intensive care unit of the Regional Hospital Lic. Adolfo López Mateos of the Institute for Social Security and Services for State Workers to reduce cytokine storm and contribute to the favorable resolution of respiratory insufficiency and multiple organic failure.
Timeline
- Start
- 2020-08-01
- Primary completion
- 2020-11-30
- Completion
- 2020-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | mesenchymal stem cells | Cell therapy | 1e+06 cells/kg | Intravenous |